News

Meeting Report: Pharma venturing

Country
Switzerland

Corporate venture capitalists increasingly are looking for early biotech investment opportunities that will support the strategic objectives of their parent companies. And they are reserving funds to support these companies until the assets in question mature. This was one conclusion from a panel discussion among venture capitalists that took place at the Sachs Investor Forum in Zurich, Switzerland on 13 September 2011.

Seven new medicines get positive opinions

Country
United Kingdom

Seven new medicines, including a new diabetes treatment, an antibiotic for C. difficile, two drugs for HIV, and combination treatments for hypertension, have received positive opinions from the European Medicines Agency.

Soliris approved for paediatric blood disorder

Country
United States

The US Food and Drug Administration has approved the monoclonal antibody, Soliris (eculizumab), for a rare paediatric blood disorder called atypical hemolytic uremic syndrome while the EMA has recommended approval of the same indication.

EMA recommends new antibiotic

Country
United Kingdom

The European Medicines Agency is recommending approval of a new macrocyclic antibiotic for Clostridium difficile, Dificlir (fidaxomicin). Developed by Optimer Pharmaceuticals Inc, the antibiotic was approved by the FDA in May 2011.

EMA recommends restrictions on Multaq

Country
United Kingdom

The European Medicines Agency has recommended restrictions on the use of Multaq (dronedarone), an anti-arrhythmic medicine marketed by Sanofi SA, due to an increased risk of liver, lung and cardiovascular adverse events.

EMA starts review of orlistat medicines

Country
United Kingdom

The European Medicines Agency has started a review of orlistat-containing medicines, which are used to treat obesity, to determine whether very rare cases of liver injury affect the medicines’ overall benefit-risk profile.

Newly-merged Sinclair IS Pharma gains pace

Country
United Kingdom

Sinclair IS Pharma Plc, which was created through the merger of two UK speciality pharmaceutical companies, has ended its 2011 financial year with a pre-tax loss, but a rise in like-for-like sales and plans for several product launches.

NovImmune starts PoC study in liver disorder

Country
Switzerland

Privately-held NovImmune SA of Geneva, Switzerland has announced the start of a proof-of-concept study of a monoclonal antibody intended to neutralise the activity of the chemokine, IP-10, in order to treat patients with primary biliary cirrhosis.

Cardio3 BioSciences opens US office

Country
Belgium

Anticipating the start of Phase 3 trials of a stem-cell therapy for heart failure, Cardio3 BioSciences SA has set up a US subsidiary in Rochester, Minnesota, the home of its minority shareholder – the Mayo Clinic. The trials are set to begin in 2012.